To evaluate whether the survival difference for lung adenocarcinoma patients with high PCK1 level could be accounted for by using in vitro model, we performed knockdown of PCK1 in patient-derived organoids, which also led to suppression of organoid growth (Fig. 6J, K). Here, PCK1 is linked to lung adenocarcinoma.